NRG receives award to develop therapies for Parkinson’s and MND
In vitro, NRG’s investigational therapies were found to offer protection to mitochondria and avert brain cell death.

In vitro, NRG’s investigational therapies were found to offer protection to mitochondria and avert brain cell death.
In a Phase III trial, ABBV-951 offered statistically significant improvement in ‘On’ time without troublesome dyskinesia.
Recent advancements in late-stage therapies for geographic atrophy have raised hopes of ushering in its first wave of therapies.
ByAccording to the deal, Pfizer will acquire CGRP programmes of Biohaven, including rimegepant, zavegepant and five pre-clinical assets.
The latest approval is based on findings from the Phase II/III N-MOmemtum clinical trial carried out in 25 countries.
Data were presented for several complement-targeting therapeutics at the American Academy of Neurology (AAN) 2022 Annual Meeting.
ByLysogene will oversee the preclinical, clinical development, production, regulatory works and marketing of the drug.
Some FDA panelists cited concerns with the ALS trial design, while others pointed to positive data and the high unmet…
ByThank you for subscribing to Pharmaceutical Technology